Current Report Filing (8-k)
May 25 2016 - 10:14AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
May
25, 2016 (May 20, 2016)
HEMISPHERX
BIOPHARMA, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0
-
27072
|
|
52-0845822
|
(state
or other juris-
|
|
(Commission
|
|
(I.R.S.
Employer
|
diction
of incorporation)
|
|
File
Number)
|
|
(Identification
No.)
|
1617
JFK Boulevard, Suite 500, Philadelphia, PA
|
|
19103
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
|
|
|
|
Registrant's
telephone number, including area code:
(215) 988-0080
|
|
|
|
1617
JFK Boulevard, Suite 500, Philadelphia, PA 19103
|
|
(Former
name or former address, if changed since last report)
|
|
|
|
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
|
Item
8.01 Other Events
On
May 23, 2012, Hemispherx Biopharma, Inc. (the “Company”) issued a press release to announce that the company executed
an amended and restated agreement with Impatients, N.V., for the commencement and management of an Early Access Program (EAP)
in all of Europe and Turkey.
A
copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No. Description
99.1
Press Release dated May 24, 2016
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
HEMISPHERX
BIOPHARMA, INC.
|
|
|
May
25, 2016
|
By:
|
/s/ Thomas K. Equels
|
|
|
Thomas K. Equels, President & CEO
|
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Apr 2023 to Apr 2024